55 patents currently held

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Oct 2028

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028 20292030203120322033203420352036 2037 2038 2039 2040 2041 2042 2043 20442045

notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Genetically-Modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene US 9,889,160

The most cited patent in this portfolio, cited by 68 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.

Ends Oct 2036 · Medium confidence Also notable

Engineered Meganucleases with Recognition Sequences Found in the Human T Cell Receptor Alpha Constant Region Gene US 10,799,535

Cited by 19 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.

Ends no later than Dec 2036 · Medium confidence Also notable

Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences US 8,445,251

Cited by 33 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.

Ends Dec 2028 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 20, 2026
The maintenance fee for Engineered Meganucleases Specific for Recognition Sequences in the PCSK9 Gene (US 11,680,254) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
1 fee due Mar 12, 2027
The maintenance fee for Polynucleotides Encoding Engineered Meganucleases Having Specificity for Recognition Sequences in the Dystrophin Gene (US 11,753,630) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
2 fees due Apr 17, 2027
1 fee due Jun 26, 2027
The maintenance fee for Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) (US 11,851,680) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
1 fee due Jul 9, 2027
The maintenance fee for Engineered Meganucleases That Target Human Mitochondrial Genomes (US 11,866,747) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
1 fee due Sep 30, 2027
The maintenance fee for Treatment of Retinitis Pigmentosa Using Engineered Meganucleases (US 10,603,363) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Sep 18Assignment recorded on 1 record: Jantz, Derek and 2 others to Precision Biosciences, Inc. Recorded Sep 18, 2026, executed Oct 29, 2019. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76521, frame 321.
2 of the patents on this record were granted since Aug 17, 2026

What they patent

The 5 largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Genetically-Modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene	10 in force	to Oct 2036
Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR)	5 in force	to Apr 2040
Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences	5 in force	to Dec 2028
Polynucleotides Encoding Engineered Meganucleases Having Specificity for Recognition Sequences in the Dystrophin Gene	3 in force	to Nov 2041
Engineered Meganucleases Specific for Recognition Sequences in the Hepatitis B Virus Genome	3 in force	to Oct 2037

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,340,777	Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences In force Term ends Oct 31, 2028 · Medium confidence	In force	Term ends Oct 31, 2028	Medium confidence
US 9,434,931	Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences In force Term ends Oct 31, 2028 · Low confidence	In force	Term ends Oct 31, 2028	Low confidence
US 10,041,053	Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences In force Term ends Oct 31, 2028 · Low confidence	In force	Term ends Oct 31, 2028	Low confidence
US 12,351,839	Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences In force Term ends Oct 31, 2028 · Low confidence	In force	Term ends Oct 31, 2028	Low confidence
US 8,445,251	Rationally-Designed Single-Chain Meganucleases with Non-Palindromic Recognition Sequences In force Term ends Dec 24, 2028 · Medium confidence	In force	Term ends Dec 24, 2028	Medium confidence
US 8,338,157	Rationally-Designed Meganuclease Variants of LIG-34 and I-Crei for Maize Genome Engineering In force Term ends Mar 2, 2029 · Medium confidence	In force	Term ends Mar 2, 2029	Medium confidence
US 9,683,257	Recognition Sequences for I-Crei-Derived Meganucleases and Uses Thereof In force Term ends Sep 22, 2029 · Medium confidence	In force	Term ends Sep 22, 2029	Medium confidence
US 10,273,524	Recognition Sequences for I-Crei-Derived Meganucleases and Uses Thereof In force Term ends Sep 22, 2029 · Low confidence	In force	Term ends Sep 22, 2029	Low confidence
US 10,287,626	Recognition Sequences for I-Crei-Derived Meganucleases and Uses Thereof In force Term ends Sep 22, 2029 · Low confidence	In force	Term ends Sep 22, 2029	Low confidence
US 10,662,440	Self-Limiting Viral Vectors Encoding Nucleases In force Term ends Jun 20, 2036 · High confidence	In force	Term ends Jun 20, 2036	High confidence

10 of 55 patents shown.

Pro members see all 55.

Pro members: see all 55 patents

Also on record, not counted in the 55: 1 patent in force now held by others · 1 patent ended · 33 applications pending · 70 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Precision Biosciences, Inc.